Login to Your Account

CFDA OKs Chongqing Zhifei's meningococcus-haemophilus flu vaccine

By Cornelia Zou
Staff Writer

Wednesday, April 23, 2014

HONG KONG – The CFDA gave the green light to Chongqing Zhifei Biological Products Co. Ltd. (SZ:300122) to launch its joint vaccine against group A and C meningococcus and haemophilus influenzae type B (AC-Hib). Zhifei's subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., developed the vaccine that aims to prevent infectious diseases such as meningitis, pneumonia, septicemia, cellulitis, arthritis and epiglottitis caused by group A and C meningococcus as well as type b haemophilus influenzae (Hib).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription